ISCHEMIA试验中合并糖尿病患者的结局
ISCHEMIA与ISCHEMIA-CKD试验合并分析显示,在慢性冠心病患者中,合并糖尿病者死亡或心肌梗死风险更高(HR 1.49),但无论是否合并糖尿病,或按性别、胰岛素使用、冠脉病变严重程度及左室功能分层,侵入性策略与初始保守药物治疗相比均未降低死亡或心肌梗死风险。
要点
- 合并糖尿病的慢性冠心病患者死亡或心梗风险显著增高(HR 1.49,95%CI 1.31-1.70)。
- 无论是否合并糖尿病,侵入性策略与保守药物治疗在死亡或心梗上无差异。
- 糖尿病亚组(性别、胰岛素使用、冠脉病变严重程度、左室功能)均未见侵入性策略获益。
核心结论
- 合并糖尿病的慢性冠心病患者死亡或心肌梗死风险更高,但常规侵入性管理相比初始单纯药物治疗未带来增量获益。
研究设计与样本
- ISCHEMIA与ISCHEMIA-CKD两项随机试验合并分析,共纳入5900例有完整基线数据的慢性冠心病患者,中位年龄64岁(IQR 57-70),24%为女性,中位eGFR 80 mL·min-1·1.73-2(IQR 64-95)。
主要发现
- 2553例(43%)合并糖尿病,中位HbA1c 7%(IQR 7-8),30%使用胰岛素。
- 合并糖尿病者死亡或心梗风险增加49%(HR 1.49,95%CI 1.31-1.70;P<0.001)。
- 中位随访3.1年,合并与不合并糖尿病者的调整无事件生存率分别为0.54(95% bootstrap CI 0.48-0.60)和0.66(95% bootstrap CI 0.61-0.71),绝对下降12%(95% bootstrap CI 4%-20%)。
- 使用胰岛素的女性与男性糖尿病患者调整无事件生存率分别为0.52(95% bootstrap CI 0.42-0.56)和0.49(95% bootstrap CI 0.42-0.56)。
- 无论是否合并糖尿病,或按女性性别、胰岛素使用、冠脉病变严重程度、左室功能分层,侵入性策略与保守策略在死亡或心梗上均无差异。
临床怎么用
- 对合并糖尿病的慢性冠心病患者,不应仅因糖尿病诊断而常规选择侵入性策略,初始药物治疗仍是合理选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among patients with diabetes and chronic coronary disease, it is unclear if invasive management improves outcomes when added to medical therapy. METHODS: The ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trials (ie, ISCHEMIA and ISCHEMIA-Chronic Kidney Disease) randomized chronic coronary disease patients to an invasive (medical therapy + angiography and revascularization if feasible) or a conservative approach (medical therapy alone with revascularization if medical therapy failed). Cohorts were combined after no trial-specific effects were observed. Diabetes was defined by history, hemoglobin A1c ≥6.5%, or use of glucose-lowering medication. The primary outcome was all-cause death or myocardial infarction (MI). Heterogeneity of effect of invasive management on death or MI was evaluated using a Bayesian approach to protect against random high or low estimates of treatment effect for patients with versus without diabetes and for diabetes subgroups of clinical (female sex and insulin use) and anatomic features (coronary artery disease severity or left ventricular function). RESULTS: Of 5900 participants with complete baseline data, the median age was 64 years (interquartile range, 57-70), 24% were female, and the median estimated glomerular filtration was 80 mL·min-1·1.73-2 (interquartile range, 64-95). Among the 2553 (43%) of participants with diabetes, the median percent hemoglobin A1c was 7% (interquartile range, 7-8), and 30% were insulin-treated. Participants with diabetes had a 49% increased hazard of death or MI (hazard ratio, 1.49 [95% CI, 1.31-1.70]; P<0.001). At median 3.1-year follow-up the adjusted event-free survival was 0.54 (95% bootstrapped CI, 0.48-0.60) and 0.66 (95% bootstrapped CI, 0.61-0.71) for patients with diabetes versus without diabetes, respectively, with a 12% (95% bootstrapped CI, 4%-20%) absolute decrease in event-free survival among participants with diabetes. Female and male patients with insulin-treated diabetes had an adjusted event-free survival of 0.52 (95% bootstrapped CI, 0.42-0.56) and 0.49 (95% bootstrapped CI, 0.42-0.56), respectively. There was no difference in death or MI between strategies for patients with diabetes versus without diabetes, or for clinical (female sex or insulin use) or anatomic features (coronary artery disease severity or left ventricular function) of patients with diabetes. CONCLUSIONS: Despite higher risk for death or MI, chronic coronary disease patients with diabetes did not derive incremental benefit from routine invasive management compared with initial medical therapy alone. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01471522.
引用
- Newman JD, Anthopolos R, Mancini GBJ, et al. Outcomes of Participants With Diabetes in the ISCHEMIA Trials. Circulation. 2021. PMID: 34521217. doi:10.1161/CIRCULATIONAHA.121.054439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。